Role and Clinical efficacy of Subconjunctival Injection Bevacizumab in Nonsurgical Management of Pterygium

ABSTRACT

Introduction: Pterygium progression and recurrence is acommon complication. In various studies conducted on role ofsubconjunctival depot injection of bevacizumab, nothing hasbeen standardized with regards to dosage and its frequency.The study was done with aim to assess role and clinicalefficacy of subconjunctival injection of bevacizumab as a nonsurgical treatment modality for pterygium.Material and Methods: 80 cases of pterygium were includedin this study. Study was done over a period of 12 months fromDecember 2018 to November 2019 at a tertiary care ophthalmiccentre of Northern India. In this study, three doses of 2.5 mgof bevacizumab were administered sub-conjunctivally atmonthly interval under topical anaesthesia on Outdoor PatientDepartment basis. Standard aseptic measures were observed.Results: Cases were followed up next day after each injectionand thereafter on monthly basis for three months and finallyafter 06 months of first injection. Progression of pterygiumwas noted in 8 cases. Subconjunctival haemorrhage was notedin 41 cases. Conjunctival cyst was seen in three cases whichwere punctured in OPD, however recurrence was noted afterone month in one case. No rise in Intra Ocular Pressure (IOP)was noted.Conclusions: Subconjunctival injection of bevacizumab isuseful in treatment of patients with pterygium without local orsystemic adverse effects.